Swiss National Bank Entrada Therapeutics, Inc. Transaction History
Swiss National Bank
- $137 Billion
- Q1 2025
A detailed history of Swiss National Bank transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Swiss National Bank holds 32,800 shares of TRDA stock, worth $252,232. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,800
Previous 32,800
-0.0%
Holding current value
$252,232
Previous $567,000
47.8%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding TRDA
# of Institutions
111Shares Held
28.7MCall Options Held
8.2KPut Options Held
2.3K-
Baker Bros. Advisors LP New York, NY4.87MShares$37.4 Million0.52% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$33.9 Million27.61% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$33.7 Million57.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.74MShares$21 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X02.12MShares$16.3 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $241M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...